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with Encephalocardiomyopathy
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Molecular diagnosis of mitochondrial disorders is challenging because of extreme clinical and genetic heterogeneity. By exome
sequencing, we identified three different bi-allelic truncating mutations in TANGO2 in three unrelated individuals with infancy-onset
episodic metabolic crises characterized by encephalopathy, hypoglycemia, rhabdomyolysis, arrhythmias, and laboratory findings sug-
gestive of a defect in mitochondrial fatty acid oxidation. Over the course of the disease, all individuals developed global brain atrophy
with cognitive impairment and pyramidal signs. TANGO2 (transport and Golgi organization 2) encodes a protein with a putative func-
tion in redistribution of Golgi membranes into the endoplasmic reticulum in Drosophila and a mitochondrial localization has been
confirmed in mice. Investigation of palmitate-dependent respiration in mutant fibroblasts showed evidence of a functional defect in
mitochondrial b-oxidation. Our results establish TANGO2 deficiency as a clinically recognizable cause of pediatric disease with multi-
organ involvement.Hereditary forms of pediatric metabolic myopathies pre-
senting with recurrent myoglobinuria and metabolic cri-
ses have been linked to genetic defects resulting in a
shortage of muscle energy. Affected pathways include
glycogen and (long-chain) fatty acid metabolism as well
as mitochondrial ATP production.1 In combination with
a detailed clinical phenotype, exome sequencing is widely
applied for diagnostic evaluation of individuals with sus-
pected inborn errors of metabolism and allows the identi-
fication of novel disease-implicated genes.2,3 However, in
a significant fraction of affected individuals, the genetic
defect underpinning the clinical phenotype remains
elusive. Explanations include the existence of pathogenic
sequence variants in off-target genomic regions or
sequence alterations such as copy-number variations
(CNVs) or chromosomal rearrangements that are difficult
to detect in exome datasets.
Here we report on a joint analysis of exome datasets
of three unrelated individuals sharing distinct pheno-
typic features using an analytical pipeline able to detect
clinically relevant CNVs. The pivotal features of the
affected individuals’ disease presentations were recurrent
metabolic encephalomyopathic crises hallmarked by labo-
ratory findings of hypoglycemia, elevated plasma CK ac-1Institute of HumanGenetics, Technische Universita¨t Mu¨nchen, 81675Mu¨nch
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as massive urinary excretion of lactate, ketones, and dicar-
boxylic acids. The severity and duration of such crises
were variable and response to intravenous glucose has
been observed. Prior to the first crisis, global develop-
mental delay as well as cortical signs were observed.
Although the clinical condition stabilized in the interval,
the overall disease course was characterized by progressive
neurodegeneration with epilepsy, cognitive impairment,
pyramidal and cerebellar signs, and loss of expressive lan-
guage. Optic atrophy and sensorineural hearing impair-
ment were observed in single individuals. Cardiac
involvement with severe arrhythmias (torsade de pointes,
long QT syndrome) was a consistent and potentially life-
threatening manifestation. Increased TSH concentrations
indicating hypothyroidism have been documented in all
three affected individuals. Clinical and genetic findings
are summarized in Table 1, pedigrees are shown in
Figure 1, neuroimaging findings are provided in Figure 2,
and detailed case reports are provided in the Supple-
mental Note. Informed consent was obtained from all
affected individuals or their guardians in case of minor
study participants. The study was approved by the ethical
committee of the Technische Universita¨t Mu¨nchen.en, Germany; 2Institute of HumanGenetics, Helmholtz ZentrumMu¨nchen,
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The AmericWhole-exome sequencing was performed on genomic
DNA from three unrelated affected individuals and parents
from family 3 as described previously.4 Using a frequency
filter of minor allele frequency < 0.1% in our in-house
database and public databases, we identified 10, 37, and
14 genes carrying potential compound heterozygous or
homozygous variants in individuals F1:II.2, F2:II.2, and
F3:II.1, respectively. In all individuals, TANGO2 (GenBank:
NM_152906.5) was the only gene carrying two predicted
loss-of-function alleles (Figure 1). No additional individ-
uals carrying potentially pathogenic bi-allelic TANGO2
variants were detected in 6,000 in-house control exomes.
Although the homozygous TANGO2 stop variant
c.418C>T (p.Arg140*) has been identified in individual
F2:II.2 in a first-pass analysis, its clinical relevance initially
remained unclear. The 34.6 kb exon 3–9 deletion present
in individual F3:II.1 in a homozygous state (Figure S1)
and in individual F1:II.2 in compound with a frameshift
variant (c.4delT [p.Cys2Alafs*35]) was identified only dur-
ing a second-pass analysis using a data analysis pipeline
optimized for the detection of CNVs (ExomeDepth).5 All
variants were confirmed in the affected individuals by
Sanger sequencing or allele-specific PCR (for deletion
exons 3–9) with parents being heterozygous carriers of
one variant each, in line with an autosomal-recessive
inheritance. None of the variants have been reported in a
homozygous state in public databases (1000 Genomes,
dbSNP 142) or an in-house database containing 6,000
exome datasets of individuals with unrelated phenotypes.
The frameshift variant c.4delT was absent from in-house
control exomes as well as ~120,000 alleles of the Exome
Aggregation Consortium (ExAC) Server (Cambridge, MA
[09/2015]). The stop gain variant c.418C>T has been de-
tected only once in a heterozygous state in ExAC. The fre-
quency of the 34.6 kb deletion observed in a homozygous
as well as a compound heterozygous state could not be
exactly determined in public databases due to insufficient
annotation. However, in our in-house database containing
5,300 exome datasets being analyzed for CNVs, this dele-
tion was found seven times only in a heterozygous state
resulting in a MAF of 0.13%. Speculatively, this variant
might therefore represent a more common disease allele
in European populations. In summary, the identification
of three different bi-allelic TANGO2 loss-of-function vari-
ants in three unrelated individuals with a strikingly uni-
form clinical phenotype establishes TANGO2 as a gene
confidently implicated in human disease.
The physiologic function of TANGO2 is not well under-
stood. TANGO2 was originally characterized in a genome-
wide RNA-mediated interference screen in a Drosophila
cell line.7 Depletion of TANGO2 caused the Golgi appa-
ratus to fuse with the endoplasmic reticulum (ER) and a
putative role of TANGO2 in redistributing Golgi mem-
branes into the ER was postulated.6 Furthermore, a lo-
calization of TANGO2 within the Golgi and cytosol has
been suggested.6 We therefore investigated Golgi orga-
nization by immunostaining of Giantin (rabbit polyclonalan Journal of Human Genetics 98, 358–362, February 4, 2016 359
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Figure 1. Pedigrees of Investigated Families and Structure of TANGO2
(A) Pedigrees of three families with mutations in TANGO2. Mutation status of affected (closed symbols) and healthy (open symbols)
family members shown. n.a., not available.
(B) Gene structure of TANGO2 with known protein domains of the gene product and localization of the identified mutations. Intronic
regions are not drawn to scale.anti-Giantin; 1:200; Abcam) and wheat germ agglutinin
(WGA) fluorescence conjugate (W6748, ThermoFisher).
We did not observe gross differences in Golgi organization
and dimension measured by immunofluorescence be-
tween TANGO2-mutant and control fibroblasts
(Figure S2). More recently, T10 (the mouse ortholog of
TANGO2) has been studied in more detail in the context
of 22q11.2 deletion syndrome, which is caused by hetero-
zygous 1.5–3 Mb deletions on chromosome 22 at locus
11.2.7 With an estimated prevalence of 1 in 4,000, the
22q11.2 deletion syndrome is one of the most common
microdeletion disorders and a major risk factor for schizo-
phrenia. Interestingly, 9 of the 30 genes involved in
22q11.2 deletion syndrome (OMIM: 611867) have been
shown to code for proteins localized to mitochondria
(COMT, UFD1L, DGCR8, MRPL40, PRODH, SLC25A1,
TXNRD2, TANGO2, and ZDHHC8).8 More specifically,
Maynard et al. showed a co-localization of the T10-GFP
fusion protein with a mitochondrially targeted mCherry
protein but only minimal co-localization with Golgi and
peroxisome.7 Furthermore, T10 was found robustly
expressed in the 10 k mitochondria-enriched fractions
of mice brain lysates.7 The protein sequences of
T10 (GenBank: NP_613049.2) and TANGO2 (GenBank:
NP_690870.3) are 88% identical. The first 30 amino acids,
which contain a predicted mitochondrial targeting360 The American Journal of Human Genetics 98, 358–362, Februarysequence (amino acids 1–13, MITOPROT), are 100% iden-
tical (Figure S3). Together, these observations suggest a
mitochondrial localization of the gene products coded by
TANGO2. The identification of the clinically relevant
variant c.4delT, which affects only the coding sequence
of the predicted mitochondrial isoforms, supports an
involvement of mitochondrial metabolism in the patho-
genesis of the disease.
Biochemical analyses of respiratory chain enzyme activ-
ities performed on muscle biopsies of individuals F2:II.2
and F3:II.1 showed normal results apart from a mild reduc-
tion in complex I activity in individual F2:II.2. Western
blot studies in fibroblasts did not indicate a decrease in
the amount of the mitochondrial respiratory chain com-
plex I subunit NDUFB8 (Figure S4). Furthermore, measure-
ment of pyruvate-dependent oxygen consumption rates9
in fibroblast cell lines from individuals F1:II.2 and F2:II.2
was unremarkable. Together, these findings make it un-
likely that primary dysfunction of the respiratory chain
follows from TANGO2 deficiency, although a transient
impairment during metabolic crises cannot be excluded.
The metabolic signature observed in the investigated in-
dividuals is characterized by ketonuria, excretion of dicar-
boxylic acids (including glutaric and malonic acid) and
lactate as well as a variable elevation of several acylcarnitine
species. Just like the laboratory findings, the clinical4, 2016
Figure 2. Neuroimaging Findings in TANGO2Mutant Individuals
(A–D) Brain MRIs of individuals F2:II.2 (A–C) and F3:II.1 (D). Although the individual MRI findings are nonspecific, the rather uniform
pictures with widening of the ventricles should be noted when placing them side by side.
(A) Brain MRI (T1-weighted image, axial view) at the age of 2 11/12 years, demonstrating mild widening of the ventricles suggestive of a
generalized brain atrophy.
(B) Brain MRI (T2-weighted image, axial view) at the age of 2 years, demonstrating mild widening of the ventricles and the bifrontal
cerebrospinal fluid spaces.
(C) Brain MRI (T2-weighted image, axial view) at the age of 6 years, showing no relevant changes compared to the earlier investigation.
(D) Diffusion-weighted imaging (axial view) at the age of 6 years during acute metabolic crisis and recurrent seizures showing extensive
left-hemispheric cortical cytotoxic edema, possibly caused by prolonged focal status epilepticus.
(E) Brain MRI (T2-weighted image, axial view) at the age of 22 years, demonstrating widening of the ventricles as a sign of generalized
brain atrophy.phenotype shows strong overlaps with disorders of mito-
chondrial fatty acid and ketone body metabolism such as
carnitine palmitoyltransferase II (CPT2) deficiency
(OMIM: 11600649, 608836, 255110) and multiple
acyl-CoA dehydrogenase deficiency (MADD [OMIM:
11231680]).10 To test a potential impact of TANGO2 defi-
ciency on mitochondrial fatty acid oxidation, we tested
palmitate-dependent mitochondrial respiration in control
and mutant fibroblasts as described previously.11 We
observed a significant difference in palmitate-dependent
oxygen consumption rate suggesting a functional defect
in mitochondrial b-oxidation of fatty acids (Figure 3).
Although further studies are needed to determine the phys-
iological function of TANGO2, it is tempting to speculateP
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Figure 3. Investigation of Palmitate-Dependent Mitochondrial
Respiration
Analysis of palmitate-dependent oxygen consumption rates
(OCR) in fibroblast cell lines revealed impaired respiration in
TANGO2-mutant cells in comparison to controls. A MCAD (me-
dium-chain acyl-Coenzyme A dehydrogenase)-deficient cell line
was used as a positive control. The experiment was performed
several times with very similar results. The data are shown from
one experiment performed with more than 12 replicates for each
cell line grown and treated in parallel. Error bars indicate 1 SD
from the mean. *p < 0.001; two-tailed unpaired t test.
The Americthat TANGO2 deficiency is associated with impaired elec-
tron transfer from FAD-dependent dehydrogenases to the
mitochondrial respiratory chain or cofactor metabolism.
In conclusion, we describe bi-allelic loss-of-function var-
iants in TANGO2 as a cause of metabolic crises with onset
in childhood potentially triggered by a catabolic metabolic
state. It is possible that the individuals reported in this
study present the severe end of the phenotypic spectrum.
Our study suggests TANGO2 deficiency as a differential
diagnosis in cases of episodic encephalopathy and/or
myopathy in infancy and childhood of unknown cause,
especially in individuals with cardiac arrhythmias and lab-
oratory findings suggestive of impaired mitochondrial
fatty acid oxidation.Supplemental Data
Supplemental Data include case reports and three figures and can
be found with this article online at http://dx.doi.org/10.1016/j.
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